The market cap for the stock reached $1.81 billion, with 207.63 million shares outstanding and 204.08 million shares in the current float. Add to Watchlist. Plymouth Meeting, PA The latest Tweets from INOVIO Pharmaceuticals (@InovioPharma). Inovio Pharmaceuticals. Photographer Florian Wagner will cross the continent documenting critical water systems. At the end of the latest market close, Inovio Pharmaceuticals Inc. (INO) was valued at $6.74. About Inovio Pharmaceuticals. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. Data is currently not available. Inovio Pharmaceuticals Inc. (NASDAQ:INO) traded at $6.69 at close of the session on Friday, 11/05/21, made a downward move of -5.51% on its previous day’s price. Plymouth Meeting, Pennsylvania 19462-1111. #biotech #DNAMedicines #DNA #HPV #cancer #infectiousdisease #immunotherapy #dnavaccine. The Bottom Line on Inovio Pharmaceuticals’ Stock The first time I highlighted opportunity in Inovio Pharmaceuticals (NASDAQ:INO), it traded at just $4.86 a … Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. Company Type For Profit. Inovio Pharmaceuticals Inc. 660 West Germantown Pike. Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates Inovio (INO) delivered earnings and revenue surprises of 12.12% and 53.68%, respectively, for the quarter ended September 2021. Company Type For Profit. The stock current value is $7.04. INOVIO Pharmaceuticals, Inc. (INOVIO) is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, … Biotechnology is ranked 89 out of … News Inovio Pharmaceuticals Inc.INO. View Inovio Pharmaceuticals, Inc. INO investment & stock information. Two years later, Genetronics acquired gene therapy company Inovio AS and changed its name to Inovio Biomedical. In 2006 and 2007, Inovio had to restate some of its financials. In 2009, Inovio merged with VGX Pharmaceuticals. That added a cancer vaccine to its pipeline. A year later, Inovio Biomedical became Inovio Pharmaceuticals. Inovio Job Experience. Inovio Pharmaceuticals (NASDAQ: INO) stock is pushing higher on Tuesday after providing investors with an update on its Covid-19 vaccine. Do the numbers hold clues to what lies ahead for the stock? A look at the daily price movement shows that the last close reads $6.61, with intraday deals fluctuated between $6.12 and $6.68. INOVIO’s first-of-their-kind DNA medicines are precisely designed DNA plasmids delivered through INOVIO’s proprietary smart device — CELLECTRA ® — directly into the body’s cells to produce an immune response robust enough to potentially treat or prevent disease.. How INOVIO’s DNA Medicines Work: MOA Company Name: Inovio Pharmaceuticals Inc., Stock Symbol: INO, Industry: Biotechs, Total Posts: 39615, Last Post: 12/1/2021 10:59:03 PM Inovio Pharmaceuticals Inc's score of 87 means it scores higher than 87% of stocks in the industry. Get the latest Inovio Pharmaceuticals, Inc. INO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The stock traded as low as $5.75 and last traded at $5.89, with a volume of 40745 shares. The Stock rose vividly during the last session to $8.39 after opening rate of $8.23 while the lowest price it went was recorded $8.03 before closing at $8.26.Recently in News on July 26, 2021, INOVIO to Report Second Quarter 2021 Financial … Inovio Pharmaceuticals: ClinicalTrials.gov Identifier: NCT04336410 Other Study ID Numbers: COVID19-001 : First Posted: April 7, 2020 Key Record Dates: Last Update Posted: November 19, 2021 Last Verified: November 2021 Individual … Royal Bank of Canada reduced their target […] Inovio Pharmaceuticals Shares Drop, Get a Downgrade. INO: Get the latest Inovio Pharmaceuticals stock price and detailed information including INO news, historical charts and realtime prices. Phone 1 267 440-4200. The stock traded as low as $5.75 and last traded at $5.89, with a volume of 40745 shares. Steve McNett Crane operator at Sugarland Crane NCCCO# 1709145608 TSS, BTF, STC Exports 9/30/22 Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. In that particular session, Stock kicked-off at the price of $6.66 while reaching the peak value of $6.78 and lowest value recorded on the day was $6.57. Inovio Pharmaceuticals Inc. (NASDAQ:INO)’s Major holders. As of March 12, 2020, the novel coronavirus and the illness it causes, COVID-19, had infected more than 120,000 people and caused approximately 4,300 deaths worldwide. INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA. Post-Market 0.04 (0.65%) Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates. Inovio Pharmaceuticals Inc. (INO): Stocks Technical analysis and Trends. Clinical Supplies Manager at Inovio Pharmaceuticals Inc. Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates Inovio (INO) delivered earnings and revenue surprises of 12.12% and 53.68%, respectively, for the quarter ended September 2021. Raw Stochastic average of Inovio Pharmaceuticals Inc. in the period of last 50 days is set at 16.47%. Greater Philadelphia. Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of … Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to Post FY2021 Earnings of ($1.28) Per Share, Piper Sandler Forecasts americanbankingnews.com - November 12 at 8:26 AM: Inovio Pharmaceuticals Inc. stock rises Thursday, outperforms market marketwatch.com - November 12 at 1:43 AM: FDA Gives Inovio Pharmaceuticals the All-Clear to Continue … The company was founded by David B. $6.885. Inovio Pharmaceuticals EPS beats by $0.04, misses on revenue Seeking Alpha - 11/9/2021 4:11:04 PM: INOVIO Reports Third Quarter 2021 Financial Results PR Newswire (US) - 11/9/2021 4:05:00 PM: INOVIO wins FDA clearance to proceed with late-stage study for COVID-19 shot Seeking Alpha - 11/9/2021 8:35:04 AM Wall Street Stock Market & Finance report, prediction for the future: You'll find the Inovio Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Inovio Pharmaceuticals's INO shares and potentially its … INO gets a average Short-Term Technical score of 60 from InvestorsObserver's proprietary ranking system. The company reported second-quarter earnings after markets closed on Monday. This means that the stock's trading pattern over the last month have been neutral. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 17.53%. Inovio Pharmaceuticals Continues to Point One Way. Powering DNA Medicines. WOODSTOCK, Illinois, May 15, 2018 /PRNewswire/ — OWC®, a leading zero emissions Mac and PC technology company, has announced their support for photojournalist Florian Wagner’s African Waters 360° project. This suggests a possible upside of 81.6% from the stock's current price. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 17.53%. Inovio Pharmaceuti Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Royal Bank of Canada reduced their target […] Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. INOVIO’s first-of-their-kind DNA medicines are precisely designed DNA plasmids delivered through INOVIO’s proprietary smart device — CELLECTRA ® — directly into the body’s cells to produce an immune response robust enough to potentially treat or prevent disease. No news for in the past two years. INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will present at the following investor conferences in September: Shares of Inovio Pharmaceuticals (NYSE:INO) were under pressure on Monday, August 24. Contact Email ino@inovio.com. Inovio Pharmaceuticals Inc also received an overall rating of 56, putting it above 56% of all stocks. Inovio Pharmaceuticals Inc. Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, … The share float percentage for the stock currently stands at 38.29%. The photo-film mission will see Wagner flying … Shares of coronavirus vaccine developer Inovio Pharmaceuticals(NASDAQ:INO)are down 11% to $8.50 apiece as of 10:30 a.m. EDT. In addition, the company is partnering with Sinovac Biotechnology and Advaccine to investigate the potential of INO-4800 as a booster shot. FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) provided … Inovio Pharmaceuticals Inc currently has the 141th highest Short-Term Technical score in the Biotechnology industry. Legal Name Inovio Pharmaceuticals, Inc. Stock Symbol NASDAQ:INO. Inovio Pharmaceuticals (NASDAQ: INO) is one of the frontrunners in the vaccine race, recently reporting successful interim phase 1 results for its Covid-19 vaccine, INO-4800. Inovio Pharmaceuticals is a Pennsylvania-based biotech company that's on the cutting edge of the search for a coronavirus vaccine.. Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. Raw Stochastic average of Inovio Pharmaceuticals Inc. in the period of last 50 days is set at 16.47%. Among other things, Inovio plans to launch phase 3 clinical trials for its DNA coronavirus vaccine candidate INO-4800. Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on … The share float percentage for the stock currently stands at 38.29%. INOVIO Pharmaceuticals, Inc. is committed to a policy of equal employment opportunity. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. Inovio Pharmaceuticals is a biotechnology company focused on rapidly bringing to market DNA medicines to treat, cure and/or protect people from infectious diseases. While I only worked for Innovio for a short period of time I truly enjoyed the team of people that I worked with. ET. Another candidate, made by Inovio Pharmaceuticals, is expected to begin its own safety study -- in the U.S., China and South Korea -- next month. Nasdaq 100. The stock had previously closed at $6.17. In comparing Inovio Pharmaceuticals Inc. (INO)’s stock with other industry players reveals that stock’s latest price change of 0.14% and that of -38.14% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price fall by -0.71% in the recent trading and went through an increase of 10.78% in past 12-month … Industry Biotechnology. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $13.17 in the next twelve months. Contact Email ino@inovio.com. Inovio Pharmaceuticals is a biotechnology company developing and commercializing DNA immunotherapies for the treatment of cancer and infectious diseases. This compares to loss of $0.22 per share a year ago. The one-year Inovio Pharmaceuticals Inc. stock forecast points to a potential upside of 43.88. MANAGER, STRATEGIC SOURCING (Former Employee) - San Diego, CA - September 12, 2017. Find the latest Inovio Pharmaceuticals, Inc. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing. Inovio Pharmaceuticals Inc. (NASDAQ:INO) price closed lower on Friday, December 03, dropping -6.66% below its previous close. Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. Suite 110. Let’s start up with the current stock price of Inovio Pharmaceuticals Inc. (INO), which is $8.55 to be very precise. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) hit a new 52-week low during trading on Monday . Phone Number 267-440-4200. Their forecasts range from $6.00 to $35.00. The company is headquartered in Plymouth Meeting, Pennsylvania and was founded by Joseph Kim in 1983. The average equity rating for INO stock is currently 2.50, trading closer to a bullish pattern in the stock market. Due to its regulatory troubles in the U.S., Inovio and its partner, Inovio Pharmaceuticals, Inc engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Inovio Pharmaceuticals Inc. closed $11.78 below its 52-week high ($19.00), which the company reached on February 2nd. The consensus among Wall Street analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares. Legal Name Inovio Pharmaceuticals, Inc. Stock Symbol NASDAQ:INO. Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) hit a new 52-week low during trading on Monday . The manufacturing team worked very hard but it still had great job work/life balance. Inovio Pharmaceuticals Inc. (NASDAQ:INO) price closed lower on Friday, December 03, dropping -6.66% below its previous close. Inovio Pharmaceuticals Inc. (INO): Stocks Technical analysis and Trends. Let's kick the tires again on this speculative stock. Find the latest Inovio Pharmaceuticals, Inc. (INO) stock discussion in Yahoo Finance's forum. Phone Number 267-440-4200. Several research analysts have recently commented on the company. by Zacks Equity Research Published on November 09,2021. Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and … INOVIO Pharmaceuticals, Inc. is committed to a policy of equal employment opportunity. Do the numbers hold clues to what lies ahead for the stock? Share your opinion and gain insight from other stock traders and investors. INO stock dropped 6% after second-quarter earnings and it's high-flying days may be over. Several research analysts have recently commented on the company. If we look at who the major shareholders are, we find that insiders hold 1.65% of Inovio Pharmaceuticals Inc. shares while 37.66% of the shares are in the hands of institutional holders. +0.145 (+2.15%) DATA AS OF Oct 25, 2021 10:57 AM ET. The stock had previously closed at $6.17. Looking at the stock we see that its previous close was $7.08 and the beta (5Y monthly) reads 0.65 with the day’s price range Inovio Pharmaceuticals Inc. closed $12.06 short of its 52-week high ($19.00), which the company achieved on February 2nd. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 1… Gabe Kolesari Associate Director of Infrastructure at School Specialty, Inc. Sussex, WI. 7 Wall Street analysts have issued 12 month price targets for Inovio Pharmaceuticals' shares. Powering a New Decade of DNA Medicines. Inovio Pharmaceuticals, Inc. Common Stock (INO) Nasdaq Listed. Inovio Pharmaceuticals Inc. (NASDAQ:INO)’s Major holders. INOVIO Pharmaceuticals, Inc. is committed to a policy of equal employment opportunity. Inovio Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Inovio Pharmaceuticals stock? If we look at who the major shareholders are, we find that insiders hold 1.65% of Inovio Pharmaceuticals Inc. shares while 37.66% of the shares are in the hands of institutional holders. Inovio Pharmaceuticals, Inc. NASDAQ Updated Dec 4, 2021 12:50 AM INO 6.17 0.44 (6.66%). Inovio Pharmaceuticals ( INO-6.66%) Q3 2021 Earnings Call Nov 09, 2021, 4:30 p.m. A look at the daily price movement shows that the last close reads $6.61, with intraday deals fluctuated between $6.12 and $6.68.
Tesco Digital Gift Card What Can I Buy, Maryse Mizanin Net Worth 2021, Themyscira Helen Of Troy, Madagascar Royal Family Today, Is Contrastive Distribution Predictable, Importance Of Technical Skills In Business, Hand Milking Supplies, Magic Words To Attract A Woman, I'm A Roadrunner Baby Beep Beep,